Literature DB >> 14643355

N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist.

Masaaki Hirose1, Shin-ichiro Egashira, Yasuhiro Goto, Takashi Hashihayata, Norikazu Ohtake, Hisashi Iwaasa, Mikiko Hata, Takehiro Fukami, Akio Kanatani, Koji Yamada.   

Abstract

The identification of potent and selective orexin-2 receptor (OX(2)R) antagonists is described based on the modification of N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogue 1, recently discovered during high throughput screening (HTS). Substitution of an acyl group in 1 with tert-Leucine (tert-Leu), and introduction of a 4-pyridylmethyl substituent onto the amino function of tert-Leu improved compound potency, selectivity, and water solubility. Thus, compound 29 is a promising tool to investigate the role of orexin-2 receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14643355     DOI: 10.1016/j.bmcl.2003.08.038

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

1.  Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats.

Authors:  Yonghui Li; Sa Li; Chuguang Wei; Huiying Wang; Nan Sui; Gilbert J Kirouac
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

Review 2.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

3.  Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay.

Authors:  Hong Yin; Alan Chu; Wei Li; Bin Wang; Fabiola Shelton; Francella Otero; Deborah G Nguyen; Jeremy S Caldwell; Yu Alice Chen
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

4.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

Review 5.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 6.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray.

Authors:  Hsin-Jung Lee; Lu-Yang Chang; Yu-Cheng Ho; Shu-Fang Teng; Ling-Ling Hwang; Ken Mackie; Lih-Chu Chiou
Journal:  Neuropharmacology       Date:  2016-02-18       Impact factor: 5.250

9.  Orexin-A Suppresses Signal Transmission to Dopaminergic Amacrine Cells From Outer and Inner Retinal Photoreceptors.

Authors:  Sheng-Nan Qiao; Wei Zhou; Lei-Lei Liu; Dao-Qi Zhang; Yong-Mei Zhong
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-09-01       Impact factor: 4.799

10.  Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Neuropharmacology       Date:  2019-12-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.